Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)

Mostrar otras versiones (1)

The intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients. We evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Michael K., Shrivastava-Ranjan, Punya, Chatterjee, Payel, Flint, Mike, Beadle, James R., Valiaeva, Nadejda, Schooley, Robert T., Hostetler, Karl Y., Montgomery, Joel M., Spiropoulou, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366795/
https://www.ncbi.nlm.nih.gov/pubmed/34401879
http://dx.doi.org/10.1101/2021.08.06.455494
Descripción
Sumario:The intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients. We evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2. ODBG-P-RVn showed 20-fold greater antiviral activity than GS-441524 and had near-equivalent activity to remdesivir in primary-like human small airway epithelial cells. Our results warrant investigation of ODBG-P-RVn efficacy in vivo.

Ejemplares similares